PROS-30 inhibitors represent a class of chemical compounds that specifically target and modulate the activity of the proteasome 30S subunit, a component involved in protein degradation pathways within cells. The proteasome system, particularly the 30S subunit, plays a crucial role in the regulated degradation of misfolded, damaged, or excess proteins through a highly selective ubiquitin-proteasome system. This degradation process is vital for maintaining protein homeostasis, or proteostasis, and the inhibition of the 30S subunit can lead to significant disruptions in cellular processes such as protein turnover, cell signaling, and metabolic regulation. The 30S subunit, being a key proteolytic unit within the larger proteasome structure, ensures the cleavage of peptide bonds, and its inhibition can cause an accumulation of non-degraded proteins, which can influence multiple intracellular pathways.
The mechanism by which PROS-30 inhibitors act involves direct interaction with active sites within the 30S subunit, specifically targeting catalytic residues responsible for peptide bond hydrolysis. This interaction often relies on the structural complementarity between the inhibitor and the proteasome's active site, which can involve covalent or non-covalent binding, depending on the chemical nature of the inhibitor. Many PROS-30 inhibitors are characterized by their specificity and selectivity for the proteasome subunit, as small variations in the chemical structure can result in significant differences in binding affinity and inhibitory efficiency. Research into these inhibitors often focuses on understanding the underlying structure-activity relationships (SAR), exploring how different functional groups and molecular frameworks contribute to their inhibition profiles. Detailed exploration of these compounds provides insights into the broader biological roles of proteasome activity in regulating intracellular protein equilibrium and other cellular dynamics.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may downregulate PROS-30 by altering the acetylation status of histones associated with the PSMA1 gene, leading to a condensed chromatin state and decreased transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This agent could reduce PROS-30 expression by demethylating DNA regions upstream of the PSMA1 gene, thereby disrupting binding sites for transcription factors necessary for PSMA1 gene activation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
By inhibiting proteasomal degradation, MG-132 may cause an accumulation of misfolded proteins, triggering a stress response that could decrease transcription of the PSMA1 gene as part of a broader cellular response. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib may decrease PROS-30 levels by disrupting proteasome function, which could lead to altered regulatory protein turnover and potentially downregulate PSMA1 gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This mTOR pathway inhibitor can decrease overall protein synthesis, which may include a reduction in PROS-30 expression as part of a broader attenuation of cap-dependent mRNA translation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 could downregulate PROS-30 by inhibiting the PI3K/Akt pathway, thereby reducing the phosphorylation status of downstream effectors involved in the transcription of the PSMA1 gene. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
This compound binds to DNA and inhibits RNA polymerase movement, which would decrease PROS-30 expression by preventing the transcription of the PSMA1 mRNA directly. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine may inhibit PROS-30 expression by altering endosomal and lysosomal pH, leading to impaired protein trafficking and potential secondary effects on gene expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 could downregulate PROS-30 by preventing the recruitment of positive transcription elongation factors to the PSMA1 gene promoter, thereby reducing transcriptional activity. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
This compound inhibits eukaryotic protein synthesis by blocking translocation, which would lead to a generalized decrease in protein levels including PROS-30 expression. | ||||||